Insider Sale at Mineralys Therapeutics Before December FDA Date

CEO Jon Congleton of Mineralys Therapeutics sold 10,700 shares on July 13, 2026 via a Rule 10b5-1 trading plan. The company is advancing lorundrostat for hypertension and cardiovascular complications ahead of an FDA date in December.

By Jonathan Ponciano · Motley Fool · July 16, 2026, 20:37 UTC

Insider Sale at Mineralys Therapeutics Before December FDA Date

Tickers: $MLYS

Topics: insider trading Rule 10b5-1 plan share sale

Read the full article at Motley Fool

More World news

EnterpriseDB Hires CMRD Engineering Team to Strengthen Sovereign AI Governance PR Newswire · November 12, 2026, 18:36 UTC
Alliant Credit Union Executive Meredith Ritchie Named 2027 Chicago Titan 100 Honoree PR Newswire · November 12, 2026, 18:36 UTC
Fed's Schmid Argues Construction Productivity is Key to Housing Affordability Over Interest Rate Cuts Seeking Alpha · November 12, 2026, 18:33 UTC
PROG Holdings Reports 59% GMV Growth and Announces $100 Million Share Repurchase Program Motley Fool · November 12, 2026, 18:30 UTC
Corteva Shares Plunge Over Q3 Earnings Miss and Pricing Pressures Motley Fool · November 12, 2026, 18:31 UTC
Teekay Tankers Shares Decline Despite Q3 Earnings Beat and New Vessel Orders Seeking Alpha · November 12, 2026, 18:27 UTC
U.S. 30-Year Treasury Auction Yields Rise as Demand Weakens Seeking Alpha · November 12, 2026, 18:30 UTC
Nvidia Names Colette Kress Interim CEO Following Jensen Huang's Resignation Motley Fool · November 12, 2026, 18:26 UTC
Bit Digital Reports Q3 2026 Net Income of $28.5 Million Amid Revenue Decline Motley Fool · November 12, 2026, 18:26 UTC
EZCORP Reports Strong Q4 2026 Results with Significant EBITDA and Revenue Growth Motley Fool · November 12, 2026, 18:16 UTC